(from abstract). The PI proposes to continue with studies regarding the molecular biology of retinoblastoma, focusing on the evaluation of chemotherapeutic and chemopreventative actions of vitamin D analogs (Specific Aim 1) and the identification of the mechanism of action of these compounds on retinoblastoma (Specific Aim 2). The subaims are: (I a) Determine the effectiveness and toxicity of Ia-hydroxyvitamin D2 (Ia-hydroxy-D2), and compare its potency and toxicity to 1,25-dihydroxy-16-ene-23-yne-vitarnin D3 (16,23-D3) in the treatment of transgenic and athvmic models of retinoblastoma. (Ib) Study the ability of these compounds to induce reduction tumor mass. (Ic) Compare the effectiveness of these analogs to standard chemotherapy used in the treatment of retinoblastoma and evaluate the effectiveness of vitamin D analogs as adjuvant therapy. (Id) Determine the effectiveness of these compounds on the midbrain tumors in """"""""trilateral"""""""" retinoblastoma. (Ie) Evaluate the emergence of drug-resistant subpopulations of retinoblastoma cells.
Sub aims to Specific Aim 2 are: (2a) Study the relationship of vitamin D receptors to drug therapy effectiveness. (2b) Determine the mechanism by which cell proliferation arrest is mediated by vitamin D analogs with regard to cell cycle proliferation and cell death. (2c) Establish whether the mechanism of tumor growth arrest is regulated by p53 -dependent gene expression. (2d) Determine whether I a-hydroxy-D2 and 16,23 -D3 inhibit angiogenesis in a transgenic mouse model. These studies will complete the pre-clinical investigation of the efficacy of vitamin D analogs for human treatment.

National Institute of Health (NIH)
National Eye Institute (NEI)
Research Project (R01)
Project #
Application #
Study Section
Visual Sciences A Study Section (VISA)
Program Officer
Dudley, Peter A
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Wisconsin Madison
Schools of Medicine
United States
Zip Code
Burris, Christopher K H; Raven, Meisha L; Rodriguez, Maria E et al. (2017) Bilateral Primary Mucinous Carcinoma of the Eyelid. Ophthal Plast Reconstr Surg 33:S72-S73
Rodriguez, Maria E; Burris, Christopher K; Kauh, Courtney Y et al. (2017) A Conjunctival Melanoma Causing Bloody Tears. Ophthal Plast Reconstr Surg 33:e77
Kulkarni, A D; van Ginkel, P R; Darjatmoko, S R et al. (2009) Use of combination therapy with cisplatin and calcitriol in the treatment of Y-79 human retinoblastoma xenograft model. Br J Ophthalmol 93:1105-8
van Ginkel, Paul R; Yang, William; Marcet, Marcus M et al. (2007) 1 alpha-Hydroxyvitamin D2 inhibits growth of human neuroblastoma. J Neurooncol 85:255-62
Albert, Daniel M; Scheef, Elizabeth A; Wang, Shoujian et al. (2007) Calcitriol is a potent inhibitor of retinal neovascularization. Invest Ophthalmol Vis Sci 48:2327-34
Tolleson, William H; Doss, Jason C; Latendresse, John et al. (2005) Spontaneous uveal amelanotic melanoma in transgenic Tyr-RAS+ Ink4a/Arf-/- mice. Arch Ophthalmol 123:1088-94
Albert, Daniel M; Kumar, Amit; Strugnell, Stephen A et al. (2004) Effectiveness of 1alpha-hydroxyvitamin D2 in inhibiting tumor growth in a murine transgenic pigmented ocular tumor model. Arch Ophthalmol 122:1365-9
Albert, Daniel M; Kumar, Amit; Strugnell, Stephen A et al. (2004) Effectiveness of vitamin D analogues in treating large tumors and during prolonged use in murine retinoblastoma models. Arch Ophthalmol 122:1357-62
Cullinan, Amy E; Lindstrom, Mary J; Sabet, Sina et al. (2004) Evaluation of the antitumor effects of Herpes simplex virus lacking ribonucleotide reductase in a murine retinoblastoma model. Curr Eye Res 29:167-72
Audo, Isabelle; Darjatmoko, Soesiawati R; Schlamp, Cassandra L et al. (2003) Vitamin D analogues increase p53, p21, and apoptosis in a xenograft model of human retinoblastoma. Invest Ophthalmol Vis Sci 44:4192-9

Showing the most recent 10 out of 84 publications